Cefiderocol Versus Best Available Therapy in the Treatment of Critically Ill Patients with Severe Infections Due to Resistant Gram-Negative Bacteria: A Systematic Review and Meta-Analysis.

Antibiotics (Basel) · 2024 · PMC11591197 · PMID 39596742

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Regarding clinical cure, our meta-analysis showed a trend towards a higher cure rate (not statistically significant) in the cefiderocol group; however, this trend was not observed when considering only the RCTs, although cefiderocol still demonstrated non-inferiority in this outcome compared to BAT.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.